Highlights

Immunomic Therapeutics Announces Expansion of IP Portfolio
Highlights Press Releases
Announces Issuance of Patent Related to LAMP-Vax™ Technology November 22, 2016 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced the
Read more
Immunomic Therapeutics and Astellas Pharma announce exclusive licensing agreement for LAMP-Vax platform to prevent and treat allergies
Highlights Press Releases
-Immunomic Therapeutics to receive upfront payment of $300 million plus 10 percent royalties from potential products for allergic diseases, including peanut allergy- -Immunomic Therapeutics to retain rights of LAMP-vax platform
Read more